Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-614-1 | CAS number: 1908-87-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because a pre-natal developmental toxicity study is available
Cross-reference
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June - August 1978
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted prior to GLP similar to OECD guideline 414 on the registered substance itself. The method is to be considered scientifically reasonable with minor deficiencies in documentation.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- not applicable
- GLP compliance:
- no
- Remarks:
- Test conducted prior to GLP implementation
- Limit test:
- no
- Species:
- rat
- Strain:
- Long-Evans
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BAYER AG, breeding FB 30 (in-house)
- Age at study initiation: 2.5 - 3.5 months (females), 3 - 6 months (males)
- Weight at study initiation: 192 - 254 g (females), 350 - 500 g (males)
- Fasting period before study: no
- Housing: except for mating, dams were housed individually in Makrolon type II cages under conventional conditions; for mating two females and one male were housed over night in Makrolon type III cages
- Diet (e.g. ad libitum): pelletted Altromin-R feed ad libitum
- Water (e.g. ad libitum): tap water ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-23°C
- Humidity (%): ca. 60%
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- 400 (Lutrol)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Concentration in vehicle: 0, 0.1%, 0.3%, 0.9%
- Amount of vehicle (if gavage): 5 ml/kg bw - Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1 male / 2 females
- Length of cohabitation: 1 night
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- 10 days, from gestation day 6-15
- Frequency of treatment:
- daily
- Duration of test:
- from mating to gestation day 20
- Remarks:
- Doses / Concentrations:
0, 5, 15, 45 mg/kg bw /day
Basis:
other: nominal amount - No. of animals per sex per dose:
- 25 females / dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The structurally related substance Imidazolidinthion-2 (Ethylenthiourea, ETU) was similarly applied at a dose of 45 mg/kg bw/day as positive control.
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
BODY WEIGHT: Yes
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: Uterus - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes / No / No data
Examinations included:
- Gravid uterus weight: No data
- Number of corpora lutea: No data
- Number of implantations: Yes
- Number of resorptions: Yes - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes, a certain number was examined regarding thoracic and abdominal organs
- Skeletal examinations: Yes, a certain number was examined
- Head examinations: Yes: all per litter for external malformations and sceletal anomalies - Statistics:
- Testing for statistically significant differences of treatment groups compared to control was performed using the following methods:
- Distribution-free WILCOXON rank-sum test (Wilcoxon-Mann-Whitney-U-Test) for body weight gain of females, number of implantations, resorptions, foetuses per litter, average weight of foetuses per litter and average placenta weight per litter
- Chi-Square-Test (YATES corrected) for number of needy forms as well as foetuses with bone alterations resp. malformations per litter
- Chi-Square-Test (dependent on expected frequencies), YATES corrected, or as so-called FISHER’s exact test, for the rate of inseminated and pregnant animals.
Calculations were performed in BAYER computing centre Leverkusen with an analysis program developed for embryotoxicity testing. As long as not noted otherwise, a difference is statistically significant if the probability value is below 5% (p < 0.05). - Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: slightly diminished body weight gain of dams
Details on maternal toxic effects:
See "Any other information on results incl. tables" - Dose descriptor:
- NOAEL
- Effect level:
- 15 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 45 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects. Remark: no dose- or substance-related effects
Details on embryotoxic / teratogenic effects:
See "Any other information on results incl. tables" - Dose descriptor:
- NOAEL
- Effect level:
- >= 45 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: teratogenicity
- Dose descriptor:
- NOAEL
- Effect level:
- >= 45 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: embryotoxicity
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- The study was conducted prior to GLP similar to OECD guideline 414 on the registered substance itself. The method is to be considered scientifically reasonable with minor deficiencies in documentation. Hence, the results can be considered as sufficiently reliable to assess the developmental toxicity of N-Methyl-2-thion-thiazolidin. There were no treatment-related effects in developmental parameters. The developmental NOAEL is ≥ 45 mg/kg bw/day, the highest dose tested, where already slight maternal toxicity was observed. Hence, N-Methyl-2-thion-thiazolidin does not need to be regarded as developmental toxicant.
- Executive summary:
In a developmental toxicity study (equivalent to OECD 414) N-Methyl-2-thion-thiazolidin was administered to 25 inseminated female Long-Evans rats/dose by gavage at dose levels of 0, 5, 15, or 45 mg/kg bw/day from days 6 through15 of gestation.
None of the animals died during the course of the study. After gavage of 45 mg/kg bw/day, a slightly diminished body weight gain of dams, and a tendency of growth retardation in foetuses was observed. 15 mg/kg bw/day were tolerated without any adverse effects.
The maternal LOAEL is 45 mg/kg bw/day, based on slightly diminished body weight gain of dams, and tendency of growth retardation in foetuses. The maternal NOAEL is 15 mg/kg bw/day.
There were no treatment-related effects in developmental parameters.
The developmental LOAEL could not be determined. The developmental NOAEL is ≥ 45 mg/kg bw/day, the highest dose tested.
The developmental toxicity study in the rat is classified as acceptable, and satisfies sufficiently the guideline requirements for a developmental toxicity study (OECD 414) in rats.
Effects on the dams
Morbidity
Rats of the solvent control were all healthy and did not show any changes in appearance and behaviour during the whole course of the test.
In the treatment groups, the following individual observations were made:
Table 1: Individual observations in treatment groups
Number of females with |
|||||||
Group |
Diarrhoea |
Coryza |
Bloody vagina |
Accelerated Breathing |
Slight ataxia |
White urine with sediments |
Abscess in uterus |
Control |
- |
- |
- |
- |
- |
- |
- |
5 mg/kg |
5 |
- |
- |
- |
- |
- |
- |
15 mg/kg |
1 |
2 |
- |
- |
- |
- |
- |
45 mg/kg |
1 |
- |
1 |
1 |
1 |
1 |
- |
45 mg/kg ETU |
5 |
1 |
- |
- |
- |
- |
- |
These individual observation do not allow any attribution to the applied substance or dose and are likely to be caused by infections
Mortality
None of the animals dies during the course of the study.
Body weight gain during pregnancy
The average changes in body weight are summarized in Table 2:
Table 2: Body weight gain of the dams
Group |
Body weight gain / g |
|
During treatment |
Total pregnancy |
|
Control |
62.8 |
149.7 |
5 mg/kg |
62.4 |
152.4 |
15 mg/kg |
57.8 |
143.7 |
45 mg/kg |
44.0 |
133.3 |
45 mg/kg ETU |
52.0 |
144.6 |
Body weight gain of pregnant rats is slightly reduced after gavage of either 45 mg/kg bw/day N-Methyl-2-thion-thiazolidin or ETU
Results of insemination and impregnation
Of the inseminated rats the following number were impregnated resp. pregnant at the day of the caesarean section:
Table 3: Results of insemination and impregnation
Substance |
Dose / mg/kg |
Inseminated rats |
Impregnated rats |
Pregnant rats |
||
Total |
% |
Total |
% |
|||
Control |
n/a |
25 |
23 |
92.0 |
23 |
100.0 |
Methyl-2-thion-thiazolidin |
5 |
25 |
23 |
92.0 |
23 |
100.0 |
Methyl-2-thion-thiazolidin |
15 |
25 |
22 |
88.0 |
22 |
100.0 |
Methyl-2-thion-thiazolidin |
45 |
25 |
24 |
96.0 |
24 |
100.0 |
ETU |
45 |
25 |
25 |
100.0 |
25 |
100.0 |
The rates of impregnated and pregnant treated animals does not differ significantly from control. Slight differences are in the range or normal biological variations.
Effects on intrauterine development
Embryolethality
None of the tested substances resp. doses had an embryolethal effect. Slight differences in resorption rate are in the range or normal biological variations.
Embryotoxicity and growth retardation
Methyl-2-thion-thiazolidin did not show any growth-retarding or embryotoxic effects up to highest dose tested. So-called needy forms, i.e. foetuses weighing < 3g on day 20 of pregnancy, were observed in the following numbers:
Table 4: Number of observed needy forms
Group |
Dose |
Number |
Remarks |
Control |
n/a |
10 |
In 3 litters |
Methyl-2-thion-thiazolidin |
5 mg/kg bw/day |
7 |
In 4 litters |
Methyl-2-thion-thiazolidin |
15 mg/kg bw/day |
0 |
|
Methyl-2-thion-thiazolidin |
45 mg/kg bw/day |
14 |
In 5 litters |
ETU |
45 mg/kg bw/day |
59 |
In 10 litters |
It was noticed that needy forms mainly appeared in litters in which also malformations occurred, in both control and treated animals.
Teratogenicity
In both control and treated animals malformations occurred as set out in Table 5.
Table 5: Observed malformations
Group |
Dam No. |
Number of foetuses with malformations |
Type of malformation |
Control |
2382 |
4 |
3x Telencephalonhypoplasia 3x Telencephalonhypoplasia + brain ventricle dilatation + shortening of phalanges |
2401 |
4 |
4x Telencephalonhypoplasia |
|
2452 |
4 |
4x Telencephalonhypoplasia |
|
Methyl-2-thion-thiazolidin, 5 mg/kg |
2430 |
3 |
3x Tail kink |
2495 |
4 |
3x Telencephalonhypoplasia 1x Telencephalonhypoplasia + Microphthalmia |
|
Methyl-2-thion-thiazolidin, 15 mg/kg |
2494 |
1 |
1x Hydrops, Sternum dysplasia, dysplasia of all long bones, general abnormality of the extremities |
Methyl-2-thion-thiazolidin, 45 mg/kg |
2385 |
2 |
2x Telencephalonhypoplasia |
2431 |
3 |
3x Telencephalonhypoplasia |
|
2456 |
4 |
3x Telencephalonhypoplasia 1x Telencephalonhypoplasia + Microphthalmia |
|
2479 |
3 |
3x Telencephalonhypoplasia |
The in the groups treated with Methyl-2-thion-thiazolidin observed Telencephalonhypoplasia are certainly not connected to the treatment as they were observed to the same extent in the control groups. This partial hypoplasia of the CNS is most probably a spontaneous mutation in this breeding line of FB30 rats. This was shown over a longer period also in other studies, but vanished after switching to another breeding line.
5 – 45 mg/kg bw/day Methyl-2-thion-thiazolidin are, solved in Polyethylene glycol 400, and applied by gavage during gestation day 6 to 15 not teratogen in Long-Evans rats.
After gavage of 45 mg/kg bw/day ETU the percentage of foetuses with minor aberrations of ossification was doubled. All foetuses in this group were malformed. Malformations affect very uniformly the neurocranium, extremities as well as spine and tail. Here, there were observed hydrocephaly, encephalomeningoceles, meningoceles, asymmetries and changes in shape as well as partial agenesis of the spine, tail kink and, regarding extremities, besides misalignments and so-called cross-legged posture, also oligo-, ektro- and syndactyly. Further, approximately half of the foetuses showed malformations on the ribs (missing, floating, fused, shortened ribs and cusp formation). With minor occurrence there were hydromyelia in the spine and spina bifida, cleft palate, abnormities on the jaws, hydronephrosis and hydroureter as well as sporadic aplasia, ectopic testicles as well as cryptorchism and sporadic open eyes observed. The distribution of the malformations is shown in Table 6.
Table 6: Distribution of malformations
Group |
Dose / mg/kg |
Number of examined foetuses |
Number of malformed foetuses |
Number of pregnant rats |
Number of dams with malformed foetuses |
|
n |
% |
|||||
Control |
0 |
265 |
12 |
4.5 |
23 |
3 |
Methyl-2-thion-thiazolidin |
5 |
270 |
7 |
2.3 |
23 |
2 |
Methyl-2-thion-thiazolidin |
15 |
251 |
1 |
0.4 |
22 |
1 |
Methyl-2-thion-thiazolidin |
45 |
277 |
12 |
4.3 |
24 |
4 |
Imidazolidinthion |
45 |
299 |
299 |
100 |
25 |
25 |
Data source
Materials and methods
Results and discussion
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
